For research and educational purposes only. Not medical advice.
Lion's mane Reference
Educational, not medical advice reference for Lion's mane: Nootropic, Cognitive; regulatory status, evidence posture, source review, and schedul…
Reference summary
Mechanistic interest centers on hericenones and erinacines, which stimulate nerve growth factor (NGF) expression in vitro and cross the blood-brain barrier in rodent models. Human evidence is modest: the Mori 2009 12-week Japanese trial in mild cognitive impairment reported cognitive-test gains that did not persist after washout, the Saitsu 2019 short trial reported subjective fatigue and mood improvement, and small trials in depression / anxiety and sleep quality show short-duration effects with wide confidence intervals. No outcome-grade evidence in Alzheimer disease, Parkinson disease, or peripheral neuropathy, despite community framing.
Regulatory and posture
- Categories
- Nootropic, Cognitive
- Aliases
- Hericium erinaceus, Yamabushitake, Hou Tou Gu, Monkey head mushroom
- Evidence posture
- human - Sold as a dietary supplement, not as an FDA-approved drug. Effects on cognition or NGF pathways are reported across small trials with mixed quality, short duration, and limited follow-up. Not a treatment for any neurological condition.
- Regulatory status
- No FDA-approved lion's mane drug label. Sold in the US as a dietary supplement (capsule, tablet, tincture, powder) and as a culinary mushroom. Active fractions discussed in the literature are hericenones from the fruiting body and erinacines from the mycelium, with very different extraction profiles between products.
- Content review status
- research reference